title: Early healing assessment with optical coherence tomography of everolimus-eluting stents with bioabsorbable polymer (synergy™) at 3 and 6 months after implantation.
abstract: OBJECTIVE
  In this study we sought to evaluate coverage and apposition of Synergy™ stent at 3 and 6 months after implantation.
  
  
  BACKGROUND
  The Pt-Cr everolimus-eluting stent with abluminal bioabsorbable polymer (Synergy™) is a new generation drug-eluting stent with features potentially favoring an early healing process which could make safe a shorter period of dual antiplatelet-therapy treatment.
  
  
  METHODS
  Prospective, two-centers study enrolling patients with similar lesions treated with Synergy™ stents undergoing examination with OCT at 3 and 6 months in the respective centers. Blinded analysis was done at a core lab. Co-primary endpoints were proportion of struts with coverage and with apposition at 3 and 6 months.
  
  
  RESULTS
  Finally, 22 patients (30 stents) in the 3 months group and 20 patients (30 stents) in the 6 months group were included. There were no significant differences between groups regarding clinical, angiographic measurements, and procedural data. The rate of strut coverage was 94.5% at 3 months and 96.6% at 6 months (P < 0.001), the rates of apposition were 93.8% and 96.2%, respectively, (P < 0.001), the proportion of uncovered but apposed struts was 2.5% and 1.9% (P = 0.03) and the proportion of uncovered and malapposed struts was 3% and 1.8%, respectively (P < 0.001). The maximal area of malapposition related with uncovered struts was 0.43 ± 0.4 mm(2) at 3 months and 0.14 ± 0.2 mm(2) at 6 months (P = 0.001).
  
  
  CONCLUSIONS
  The everolimus-eluting stent with absorbable polymer, Synergy™, is associated to a high degree of intimal coverage and apposition at 3 months after implantation with additional increase at 6 months. © 2015 Wiley Periodicals, Inc.
authors.affiliation: Unidad De Cardiología Intervencionista, Cardiología Valdecilla, Hospital Universitario Marques De Valdecilla, Santander, Spain. he1thj@humv.es.
authors.forename: Jose M
authors.initials: JM
authors.lastname: de la Torre Hernández
authors.affiliation: Unidad De Cardiologia Intervencionista, Servicio De Cardiologia, Hospital Universitario De Burgos, Bugos, Spain.
authors.forename: Paula
authors.initials: P
authors.lastname: Tejedor
authors.affiliation: Unidad De Cardiología Intervencionista, Cardiología Valdecilla, Hospital Universitario Marques De Valdecilla, Santander, Spain.
authors.forename: Tamara Garcia
authors.initials: TG
authors.lastname: Camarero
authors.affiliation: Unidad De Cardiologia Intervencionista, Servicio De Cardiologia, Hospital Universitario De Burgos, Bugos, Spain.
authors.forename: Juan M
authors.initials: JM
authors.lastname: Duran
authors.affiliation: Unidad De Cardiología Intervencionista, Cardiología Valdecilla, Hospital Universitario Marques De Valdecilla, Santander, Spain.
authors.forename: Dae-Hyun
authors.initials: DH
authors.lastname: Lee
authors.affiliation: Unidad De Cardiologia Intervencionista, Servicio De Cardiologia, Hospital Universitario De Burgos, Bugos, Spain.
authors.forename: Jairo
authors.initials: J
authors.lastname: Monedero
authors.affiliation: Unidad De Cardiología Intervencionista, Cardiología Valdecilla, Hospital Universitario Marques De Valdecilla, Santander, Spain.
authors.forename: Fermin Sainz
authors.initials: FS
authors.lastname: Laso
authors.affiliation: Unidad De Cardiologia Intervencionista, Servicio De Cardiologia, Hospital Universitario De Burgos, Bugos, Spain.
authors.forename: Marcos Alvarez
authors.initials: MA
authors.lastname: Calderón
authors.affiliation: Unidad De Cardiología Intervencionista, Cardiología Valdecilla, Hospital Universitario Marques De Valdecilla, Santander, Spain.
authors.forename: Gabriela
authors.initials: G
authors.lastname: Veiga
authors.affiliation: Unidad De Cardiología Intervencionista, Cardiología Valdecilla, Hospital Universitario Marques De Valdecilla, Santander, Spain.
authors.forename: Javier
authors.initials: J
authors.lastname: Zueco
mesh_terms: D020341:Absorbable Implants; D000368:Aged; D002317:Cardiovascular Agents / Q000008:administration & dosage* / Q000009:adverse effects; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000628:therapy*; D003331:Coronary Vessels / Q000000981:diagnostic imaging / Q000187:drug effects*; D054855:Drug-Eluting Stents; D000068338:Everolimus / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D058426:Neointima; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000295:instrumentation*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D011108:Polymers / Q000737:chemistry*; D011237:Predictive Value of Tests; D011446:Prospective Studies; D011474:Prosthesis Design; D013030:Spain; D013997:Time Factors; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D002317:Cardiovascular Agents; D010975:Platelet Aggregation Inhibitors; D011108:Polymers; D000068338:Everolimus
keywords: coronary artery disease; drug-eluting stents; optical coherence tomography